Breaking
Medicus Pharma Ltd. to Present at Biotech Showcase 2026, Advancing SkinJect ProgramEli Lilly's Legal Victory Over Noom's GLP-1 ClaimsBBSW AI Solution Event: Daily Roundup
Sunday, June 7, 2026
🇺🇸 FDA

autogene cevumeran News

🇺🇸 Americas ← All news

FDA autogene cevumeran coverage for business development, investment, and market access teams

Latest on autogene cevumeran

BioNTech doses first patient in Phase 1 pancreatic cancer mRNA vaccine trial
Newspancreatic cancerJun 7, 2026

BioNTech doses first patient in Phase 1 pancreatic cancer mRNA vaccine trial

BioNTech and Genentech have dosed the first patient in the Phase 1 pancreatic cancer mRNA vaccine trial of autogene cevumeran. Earlier Nature data showed immune responses in 8 of 16 patients and established the study as the first mRNA vaccine trial in pancreatic cancer.

Dr. Sarah Mitchell

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.